CStone to present key clinical data at ESMO 2025

CStone Pharmaceuticals announced it will present Phase I dose-escalation data for its PD-1/VEGF/CTLA-4 trispecific antibody (CS2009) and a trial-in-progress update for its ROR1 Antibody-Drug Conjugate (CS5001) at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, from October 17-21, 2025. This marks the world's first clinical data presentation for a PD-1/VEGF/CTLA-4 trispecific antibody.

The CS2009 abstract, based on data from 9 patients as of May 8, 2025, met ESMO's submission requirements. CStone plans to disclose updated preliminary data for CS2009 from approximately 70 advanced solid tumor patients during an ESMO poster presentation (Poster Number: 1545P) on Sunday, October 19, 2025. Following this, an investor meeting will be held on Monday, October 20, 2025, to discuss the presented data and future clinical development plans.

The Phase Ib study design abstract for CS5001 (ROR1-ADC) will also be presented as an electronic poster (ePoster Number: 1316eTiP), available online from Saturday, October 18, 2025. CS5001 is being investigated as a single agent and in combination with systemic therapies for advanced solid tumors and lymphomas.